Post by Hylomorph

PRESS RELEASE 📢 We are excited to share that preclinical results for Vesta™, Hylomorph’s absorbable antibacterial envelope for cardiac implantable electronic devices (CIEDs), have been published in Europace (European Society of Cardiology). 🔬 Key findings: • Complete bacterial inhibition against clinically relevant strains • Sustained antibiotic release for 7 days • Superior conformability for easier, safer implantation • Excellent biocompatibility and full absorption with normal healing 🧑‍⚕️ As the authors note, Vesta™ combines effective antimicrobial protection with advanced form-factor to address persistent challenges in cardiac device therapy. 🫀 At Hylomorph, we remain committed to bridging science and clinical need. These results reinforce our mission to improve patient outcomes through intelligent design. ⏭️ What’s next? Regulatory approval and clinical validation are underway, with hospital adoption in CIED patients planned to confirm these benefits. 📃 Read the full press release here below. #MedTech #Innovation #CIED #Cardiology #PatientSafety #Vesta #Epeeps #CardioTwitter